Article

Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.

Chemistry Department, Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, Québec, Canada H7S 2G5.
Organic Letters (impact factor: 5.86). 09/2004; 6(17):2901-4. DOI:10.1021/ol0489907 pp.2901-4
Source: PubMed

ABSTRACT The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.

0 0
 · 
0 Bookmarks
 · 
50 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

building blocks
 
convergent manner
 
multigram quantities
 
NS3 protease inhibitor